Impact of mesenchymal stromal cells on in vitro growth of fresh human myeloma plasma cells and on autologous/cord blood NK cell Mediated Cytotoxicity

Cytotherapy ◽  
2018 ◽  
Vol 20 (5) ◽  
pp. e9
Author(s):  
P. Yurdakul ◽  
H. Akin ◽  
G. Aydin ◽  
M. Bunsuz Sengun ◽  
E. Turasan ◽  
...  
Cytotherapy ◽  
2009 ◽  
Vol 11 (7) ◽  
pp. 886-896 ◽  
Author(s):  
Patricia Flores-Guzmán ◽  
Eugenia Flores-Figueroa ◽  
Juan J. Montesinos ◽  
Guadalupe Martínez-Jaramillo ◽  
Veronica Fernández-Sánchez ◽  
...  

Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S42
Author(s):  
Eliana Amati ◽  
Sabrina Sella ◽  
Martina Bernardi ◽  
Elena Albiero ◽  
Silvia Castegnaro ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1350-1350
Author(s):  
Moutih Rafei ◽  
Jeremy Hsieh ◽  
MengYang Li ◽  
Jacques Galipeau

Abstract Marrow-derived Mesenchymal Stromal Cells (MSCs) have been demonstrated to possess powerful immunomodulatory suppressive properties. In vitro studies by many groups have shown that MSCs can suppress th1 immune responses as exemplified by in vitro blockade of a 2-way mixed lymphocyte reaction (MLR) by an assortment of mechanisms including production of soluble factors such as: nitric oxide, transforming growth factor-β, IGF-1 and hepatocyte growth factor. Lately, interesting studies have also demonstrated the potency of MSCs in modulating humoral immunity by inhibiting B-cell migration, proliferation as well as immunoglobulin secretion in vitro. We here sought to further define the ability of autologous MSCs in modulating an ovalbumin (OVA) antigen-specific humoral response in normal immune competent C57BL/6 mice. Immunologically naïve mice were vaccinated with 50 ug of recombinant chicken ovalbumin protein followed by a boost dose 2 weeks later. All mice developed a robust IgM and IgG anti-OVA antibody response as measured in serial plasma samples over time. Following establishment of anti-OVA humoral immunity, test mice (n=10) were administered 1.5 million autologous MSCs in the peritoneal cavity twice at one month interval. Compared with same-treated controls (n=10), we found that MSC treated mice significantly suppressed anti-OVA IgG titer. This inhibitory effect requires metabolically active MSCs since live MSCs inhibited anti-OVA IgG secretion in ELISPOT assays, whereas paraformaldehyde fixed MSCs had no effect. Interestingly, the addition of MSC conditioned media directly on spleen-derived plasma cells derived form OVA immunized mice inhibited OVA-specific IgG secretion in vitro. A cytokine array screen on MSC secretome identified CCL2 as a possible effector molecule in suppressing plasma cell activity, and we found that anti-CCL2 neutralizing antibodies abolished the suppressive effect of MSCs on plasma cells. In conclusion, we have found that MSCs can suppress a pre-established humoral response to a defined antigen in vivo. This effect is contact independent, and requires metabolically active MSCs. MSC-derived CCL2 appears to be a key suppressor of antigen-specific immunoglobulin in this system.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4811-4811
Author(s):  
Camillo Almici ◽  
Arabella Neva ◽  
Rosanna Verardi ◽  
Simona Braga ◽  
Andrea Di Palma ◽  
...  

Abstract Abstract 4811 The number of hematopoietic stem and progenitor cells (HPCs) in cord blood units are limited and this can result in delayed engraftment. In vitro expansion of HPCs provides a perspective to overcome these limitations. Different combinations of cytokines as well as mesenchymal stromal cells (MSC) have been shown to separately support HPCs ex vivo expansion, but the combining effects are under evaluation. Data derived from ex vivo co-culture systems using MSC as a feeder layer suggest that cellular contacts could have a significant impact on expansion. We have evaluated the expansion rate of thawed cord blood samples (n=6) in a medium containing SCF (100 ng/ml) and G-CSF (100 ng/ml) plated over a pre-established bone marrow derived MSC layer in comparison to the absence of either MSC layer or cytokines. After 7 days cultures were demi-depopulated. At 14 days of culture adherent and non-adherent cells were harvested, counted and evaluated for antigens expression and clonogenic capacity. Immunophenotypic analysis was performed using CD34-PE, CD38-FITC, CD45-PE-Cy7, CD133-APC. Clonogenic assay was performed in semisolid methylcellulose culture medium (MethoCult, Stem Cell Technologies), CFU frequencies and total CFU numbers per cord blood sample were determined. After 14 days of culture, in the presence of MSC layer, an 11.2-fold increase (range 4.4–18.4) in total number of cells was observed, in comparison to a 4.8-fold increase (range1.1-10.35) in the absence of MSC layer. The presence of MSC layer generated a 4.3-fold increase (range 1.5–7.2) in the number of CD34 positive cells, compared to a 3.3-fold increase (range 0.9–5.7) in the absence of MSC; when considering the more immature CD34+/CD38− subpopulation the corresponding increase were 26.9-fold vs 2.85-fold, respectively. Moreover, the percentage of the CD34+/CD38− subpopulation was higher in the adherent compared to the non-adherent fraction (76% vs 15%). The selection effect given by the MSC layer was confirmed by the presence of hematopoiesis foci growing onto the MSC layer. Our data show that cord blood HPCs can be expanded in vitro, moreover the co-culture on a MSC layer shows a synergistic effect on TCN, CD34+ cells and on more primitive CD34+/CD38− cells. Therefore, a clinical protocol of cord blood HPCs and MSC co-culture could represent a promising approach for improving engraftment kinetics in cord blood transplant recipients. Disclosures: No relevant conflicts of interest to declare.


2020 ◽  
Vol 26 (3) ◽  
pp. S315
Author(s):  
Hasan Yalim Akin ◽  
Eylul Turasan ◽  
Ekin Kircali ◽  
Erman Akkus ◽  
Guldane Cengiz Seval ◽  
...  
Keyword(s):  

Cytotherapy ◽  
2015 ◽  
Vol 17 (11) ◽  
pp. 1506-1513 ◽  
Author(s):  
Hi-Jin You ◽  
Sik Namgoong ◽  
Seung-Kyu Han ◽  
Seong-Ho Jeong ◽  
Eun-Sang Dhong ◽  
...  

2009 ◽  
Vol 22 (05) ◽  
pp. 363-370 ◽  
Author(s):  
T. G. Koch ◽  
T. Heerkens ◽  
K. Besonov ◽  
P. D. Thomsen ◽  
D. H. Betts ◽  
...  

Summary Objective: Orthopaedic injury is the most common cause of lost training days or premature retirement in the equine athlete. Cell-based therapies are a potential new treatment option in musculo-skeletal diseases. Mesenchymal stromal cells (MSC) have been derived from multiple sources in the horse including bone marrow and umbilical cord blood. The objective of this study was to provide an in vitro comparison of the chondrogenic potential in MSC derived from adult bone marrow (BM-MSC) and umbilical cord blood (CB-MSC). Results: MSC from both sources produced tissue with cartilage-like morphology that stained positive for proteoglycans and expressed cartilage markers. The CB-MSC pellets were larger and showed hyaline-like cartilage morphology as early as day six. Gene expression of collagen type 21, aggrecan and CD-RAP was higher in CB- than BM-MSC pel-lets. Expression of Sox9 mRNA was similar between CB- and BM-MSC pellets. Protein concentration of cartilage-derived retinoic acid sensitive protein was higher in culture medium from CB- than BM-MSC pellets. Conclusion: CB-MSC and BM-MSC were both capable of producing hyaline-like cartilage in vitro. However, in this study the MSC from umbilical cord blood appeared to have more chondrogenic potential than the BMMSC based on the cells tested and parameters measured.Supplementary Information for this paper is available on the VCOT website at www.VCOTonline.com.


2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Eliana Amati ◽  
Sabrina Sella ◽  
Omar Perbellini ◽  
Alberta Alghisi ◽  
Martina Bernardi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document